Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fingolimod in schizophrenia
IRCT20090117001556N137Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of fingolimod in schizophrenia (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Severity of schizophrenia at week 8. Started Sep 2021; status: completed.
02
Drugs
fingolimod
03
Conditions
schizophrenia
Beyond the preview
Go deeper on IRCT20090117001556N137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090117001556N137.